Rhenman & Partners Asset Management Ab Bei Gene, Ltd. Transaction History
Rhenman & Partners Asset Management Ab
- $1.01 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
226Shares Held
42.1MCall Options Held
91.1KPut Options Held
78.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.05 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.36 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$963 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$718 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...